NCT02356289已完成1 期
Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 48
- 试验地点
- 1
- 主要终点
- Safety: Incidence of adverse events
研究概览
简要总结
The purpose of this study is to establish initial safety, tolerability, pharmacokinetics and pharmacodynamics of MYK-461 in human subjects. This is a randomized, double-blind, placebo-controlled, sequential group, single ascending (oral) dose study in healthy volunteers aged 18-55 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Normal body mass index (BMI)
- •Normal LVEF
- •Normal electrocardiogram (ECG)
- •Females must not be breastfeeding and must be permanently sterilized or are postmenopausal.
排除标准
- •Any structural abnormalities on echocardiography
- •Positive results of HIV test and/or seropositive for HCV or HBV.
研究组 & 干预措施
MYK-461
Experimental
single-dose, tablet formulation
干预措施: MYK-461 (Drug)
Placebo
Placebo Comparator
single-dose, tablet formulation
干预措施: Placebo (Drug)
结局指标
主要结局
Safety: Incidence of adverse events
时间窗: 28 Days
次要结局
- Determination of pharmacokinetics parameters(28 Days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461Hypertrophic CardiomyopathyNCT02329184MyoKardia, Inc.15
进行中（未招募）
1 期
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic MalignanciesNon Hodgkin LymphomaChronic Lymphocytic LeukemiaNCT03913949Ascentage Pharma Group Inc.74
招募中
1 期
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of LymphomaRecurrent or Refractory B-cell Non Hodgkin's LymphomaNCT06503211The First Affiliated Hospital with Nanjing Medical University10
撤回
1 期
3D011-08 Monotherapy in Subjects With Advanced Solid TumorsSolid Tumor, AdultNCT050995363D Medicines (Beijing) Co., Ltd.
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsAdvanced Solid TumorMSI-H/dMMR TumorsCutaneous Squamous Cell CarcinomaUrothelial CarcinomaEsophageal Squamous Cell CarcinomaCervical CancerHepatoCellular CarcinomaSmall-cell Lung CancerMesotheliomaPD-L1 Amplified Tumor (9p24.1)Merkel Cell CarcinomaNasopharyngeal CarcinomaNCT04242199Incyte Corporation182